Peptide Compounding Is Being Reopened: Where It Actually Stands

FDA removed twelve peptide bulk drug substances from Category 2 of the 503A bulk drug substances list. Category 2 is the restrictive bucket — substances FDA has identified as raising significant safety concerns, which a pharmacy may not compound with.

The twelve: BPC-157, Cathelicidin LL-37, Dihexa Acetate, Emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, Pegylated Mechano Growth Factor (PEG-MGF), Melanotan II, MOTS-c, Semax (heptapeptide), and Thymosin Beta-4 Fragment (TB-500).

The removal took effect within seven calendar days. It is worth being exact about what it accomplished: it took these substances out of the restrictive category and made them eligible for the committee review that followed. It did not place any of them on the 503A list, and it did not make any of them compoundable.

The distinction matters because "removed from the FDA's banned list" circulated widely in April as though it meant availability. It meant a procedural gate had opened.

FDA's Pharmacy Compounding Advisory Committee considered seven peptides and recommended six for inclusion on the 503A list.

Two features of this table deserve more attention than the headline count.

The margins were narrow. Six members voted against BPC-157 and one abstained. MOTS-c cleared 7–5–2. These were not consensus findings, and a recommendation carried by two votes does not describe a settled scientific question. It describes a divided panel.

One substance was rejected outright. Emideltide, better known as DSIP, went before the same committee on the same two days on the same kind of record, and did not get a recommendation. Any account of this vote that lists only the six is selling something.

FDA usually follows PCAC. Not always — it has departed from committee recommendations before, and here its own review division had argued the other way. The vote is advisory input, not a decision. What it does establish is that these substances now have a reviewed record on the docket where previously they had only a default exclusion.

The Washington Post reported that the administration is crafting plans to allow the temporary sale of certain previously restricted peptides while federal health officials write new regulations. Health Secretary Robert F. Kennedy Jr. is a self-described "big fan" of peptides and has said he wants them more broadly available. Formal rulemaking has no set date.

This is the most consequential of the three developments and also the least substantiated. What the reporting establishes, and what it does not:

The Alliance for Pharmacy Compounding, led by CEO Scott Brunner, has asked FDA for interim enforcement discretion with conditions attached — enhanced patient disclosures, serious adverse event reporting, and data collection. That is the trade body's request, not a confirmed element of the administration's plan, and the two are being conflated in some coverage.

What can reasonably be inferred is direction. An administration preparing a temporary allowance while rules are drafted is not an administration planning to leave these substances restricted. For practices built around the peptides in question, that is a materially different outlook than the one that prevailed a year ago.

What cannot be inferred is scope, timing, or conditions. A stopgap with mandatory adverse-event reporting and patient disclosure requirements is a different operating environment from one without them, and nothing published so far says which this would be.

Most of the coverage is procedural — who sat on the panel, who objected to what. The more important fact is simpler. These substances are being evaluated on their evidence, in public, for the first time. Category 2 was never a finding; it was an interim staffing decision under a 2019 policy, applied without advisory committee evaluation and without rulemaking, and once a substance landed there it stayed there. What 2026 changed is that the category itself stopped being the end of the conversation: twelve substances came off it, and the question of whether they belong on the 503A list went to a committee that had to vote on the record.

FDA's review division and its advisory committee reached different conclusions, which is what advisory committees are for. Agency scientists told the panel in late June that in their assessment the available effectiveness and safety data did not yet support compounding. The panel weighed the same record alongside clinical testimony and recommended six substances anyway. Staff and advisers disagreeing is an ordinary feature of this process rather than a defect in it — the committee exists precisely so that the evidence is weighed by people outside the review division.

The composition of the panel has been raised as an issue, which invites the obvious question of what the alternative would be. A committee convened to decide whether compounding pharmacies may work with peptides will, by design, seat pharmacists, compounders and physicians who work with them. The practitioners who use these substances clinically are the people who know how they are actually dosed, tolerated and monitored, and a panel without them would be deciding the question with less information rather than more. FDA has said the members went through the same ethics and vetting process required of every advisory committee member. HHS took a more active role in assembling this one than is typical, which is worth naming plainly — and is also the reason the question finally got asked after years of not being asked.

The sector organised, and it is working. The American Academy of Peptide Medicine commissioned polling this summer and has argued that expanding access through regulated U.S. pharmacies is both popular and the better public-health answer. Lee Rosebush has urged HHS to use temporary enforcement discretion "as soon as possible to help eliminate the gray and black market that currently exists." That is the strongest argument in the file and it is a clinical one: demand for these substances exists today, and right now it is being met largely by unregulated suppliers selling material labelled for research use. Moving that volume into licensed pharmacies is a safety improvement on its own terms, before anyone argues about efficacy.

Even the cautious view expects this to move. Ilisa Bernstein, formerly deputy director of FDA's drug compliance office, has concerns about the depth of the safety and use data but has said "it seems inevitable that the floodgates will open, and having appropriate guardrails with the enforcement discretion could help identify safety concerns." That is the realistic read of where this sits: the open question is not whether access broadens, but on what terms.

What this means for anyone operating in the category: the direction is favourable, and the terms are still being written. A loosening that arrives with conditions attached rewards the practices that already meet them — and the conditions under discussion are disclosure, adverse event reporting and outcome data, which is to say the ones the industry asked for itself. The practices that document now are the ones a broadening actually benefits.

Nothing has changed. None of the twelve substances removed from Category 2 is on the 503A list. The six recommended in July are not on the 503A list. The stopgap has not been announced.

Adding a substance to the 503A list requires notice-and-comment rulemaking: FDA reviews the docket, issues a proposed rule stating its own position, takes public comment, and issues a final rule. Only at the final rule does a substance actually join the list. There is no published timeline, and any specific date circulating is speculation.

Until then, compounding these substances under 503A is not permitted, and material sold as though it were is being sold outside that pathway.

This is also where "research use only" needs to be addressed directly, because the gap between the regulatory trajectory and present-day availability is exactly where RUO product fills in. RUO labelling is an exemption from the manufacturing standards that apply to drugs, not an authorisation for human use. Material sold that way has not been tested to any enforceable standard for identity, potency, sterility or endotoxin content. For an injectable those are not academic concerns, and independent testing of research-chemical peptides has repeatedly found contents that do not match the label.

A favourable regulatory direction does not retroactively make today's grey-market supply safe or lawful. Those are separate questions and the first does not answer the second.

It would not touch GLP-1s. This is the most common misreading, and the direction of travel there is opposite. On April 30, 2026, FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, having found no sufficient clinical need for outsourcing facilities to compound them from bulk. On September 18 it issued a Warning Letter over compounded GLP-1 combination products. Two tracks, moving in opposite directions at the same time.

The reason they differ is structural rather than political. The peptides under discussion have no approved commercial equivalent — the question is whether a pharmacy may work with the substance at all. Semaglutide and tirzepatide have approved products on the market with no shortage in effect, so an entirely different provision applies: whether a compounded version is essentially a copy of something already available.

It would not establish efficacy. Inclusion on the 503A list means a compounding pharmacy may lawfully work with a substance. It is not a finding that the substance works. A substance can sit on that list indefinitely and never be an FDA-approved drug for anything. The published human evidence for several of the six remains thin, and a favourable vote on compounding eligibility does not change what the studies show.

It would not override state boards. State boards of pharmacy retain independent authority over compounding standards regardless of FDA's position, and several states are stricter than the federal standard. For a practice operating across state lines, federal permission is a floor, not an answer.

It would not resolve WADA status. BPC-157 remains on the prohibited list regardless of its compounding status. Tested athletes should continue to treat it as disqualifying.

Watch the docket, not the headlines. The step that matters next is a proposed rule, because that is where FDA states its own position rather than the committee's. It may differ. Nothing before it changes what is lawful.

Do not pre-position on an unannounced plan. Stocking, marketing or promising availability on the strength of October reporting means committing to a scope and a timeline nobody has published. The plan is explicitly described as able to change.

Keep the substances straight. Six recommended, one rejected, twelve removed from Category 2 — these are three different sets, and conflating them is how a practice ends up claiming something about DSIP that the record does not support.

Be the source that states it accurately. The gap between what happened and what is being said about it is unusually wide right now, and patients are reading the wider version. A practice that explains the vote margins, names the rejected substance and says plainly that nothing has changed yet is doing something its competitors are not.

Adopt the conditions before they are conditions. The industry's own petition asks for enforcement discretion coupled with enhanced patient disclosure, serious adverse event reporting, and data collection on peptide use. Those are not burdens invented by regulators; they are the terms the sector proposed for itself. A practice that already discloses regulatory status in writing at the point of prescribing, already reports adverse events through a defined channel, and already collects structured outcome data on every peptide protocol it runs is not scrambling to comply if a stopgap arrives with strings attached — and is not exposed if it arrives, is challenged, and is withdrawn. The conditions cost little to meet now and are the whole difference between a documented practice and an opportunistic one.

The direction of travel is favourable. It is also incomplete, and the distance between a committee recommendation and a final rule is where most of the inaccurate claims in this category currently live.

• Rachel Roubein, Trump administration paving way for temporary sale of some unapproved peptides, Washington Post — October 7, 2026
• Orrick, FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings — April 2026
• Frier Levitt, FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List
• CNN, FDA advisers support easing restrictions on six peptides — July 31, 2026
• Polsinelli, What FDA's Latest Actions Mean for Peptide Compounding
• FDA, Pharmacy Compounding Advisory Committee — July 23–24, 2026 meeting materials
• FDA, Bulk Drug Substances Used in Compounding Under Section 503A
• FDA, Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — April 30, 2026

This article is commentary on published regulatory materials and press reporting. It is not legal advice, and it is not a recommendation to use any substance discussed. Prescribers should consult healthcare counsel on how these provisions apply in the states where they practise.